视觉获益与视力提升:基线协变量在治疗组相对对照组中的效应——ANCHOR与MARINA汇总分析
本研究为ANCHOR与MARINA两项III期研究的汇总事后分析,纳入nAMD患者(对照组n=323,雷珠单抗组n=332),基线BCVA≥35-<85个字母。雷珠单抗组在12个月和24个月时校正平均BCVA分别优于对照组18.9和21.2个字母。基线BCVA越高,BCVA提升越低,但达到最终BCVA>69个字母的可能性越大。
要点
- 雷珠单抗组12个月校正平均BCVA优于对照组18.9个字母,24个月优于21.2个字母
- 雷珠单抗治疗、较高基线BCVA、较低年龄和较小病灶与达到BCVA>69个字母正相关
- 24个月时各基线BCVA亚组的治疗组与对照组平均BCVA提升差值相似:≥35-<55字母组21.9个字母,≥55-<70字母组25.2个字母,≥70-<85字母组19.3个字母
核心结论
- 较高基线BCVA与较低的BCVA提升相关,但因达到应答所需提升较小,达到最终BCVA>69个字母的可能性更大。
- 评估nAMD治疗应答时应考虑视觉获益,包括视力维持、最终达到的视力以及相对于自然疾病进展的相对提升。
研究设计与样本
- ANCHOR和MARINA两项III期研究的事后汇总分析,评估雷珠单抗治疗nAMD。
- ANCHOR纳入83个国际中心,MARINA纳入美国96个中心。
- 分析纳入nAMD且基线BCVA≥35-<85个字母的患者,对照组n=323,雷珠单抗组n=332。
主要发现
- 雷珠单抗组12个月校正平均BCVA优于对照组18.9个字母,24个月优于对照组21.2个字母。
- 雷珠单抗治疗、较高基线BCVA、较低年龄和较小病灶与达到BCVA>69个字母正相关。
- 基线BCVA最高的患者BCVA提升最低。
- 雷珠单抗治疗、较低基线BCVA、较低年龄和较小病灶是24个月时BCVA较基线提升的显著预测因素(均p<0.0001)。
- 24个月时治疗组与对照组平均BCVA提升差值在各基线BCVA亚组相似:≥35-<55字母组21.9个字母,≥55-<70字母组25.2个字母,≥70-<85字母组19.3个字母。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to elucidate visual benefits of ranibizumab in patients with neovascular age-related macular degeneration (nAMD) compared with control arms and identify factors affecting response. METHODS: This is a post-hoc pooled analysis of two phase III studies, ANCHOR and MARINA, of ranibizumab for the treatment of nAMD. ANCHOR included 83 international sites. MARINA included 96 sites in the USA. Analysis included patients (control, n=323; ranibizumab, n=332) with nAMD and a baseline best-corrected visual acuity (BCVA) of ≥35-<85 letters. RESULTS: Patients receiving ranibizumab achieved an adjusted mean BCVA superiority of 18.9 and 21.2 letters over 12 and 24 months, respectively, compared with control. Ranibizumab treatment, higher baseline BCVA, lower age and smaller lesion size were positively associated with the ability to achieve BCVA >69 letters. Patients with the highest baseline BCVA had lowest BCVA gains. Ranibizumab treatment, lower baseline BCVA, lower age and smaller lesion size were identified as significant predictors of BCVA gain from baseline at month 24 (all p<0.0001). However, the difference in mean BCVA gains at month 24 between treatment and control groups was similar for all baseline BCVA subgroups (≥35-<55 letters, 21.9 letters; ≥55-<70 letters, 25.2 letters; ≥70-<85 letters, 19.3 letters). CONCLUSIONS: Higher baseline BCVA is associated with lower BCVA gains but a greater likelihood of achieving good final BCVA >69 letters due to smaller gains needed to achieve response. Visual benefits, including maintenance of visual acuity (VA), final VA achieved and relative gain compared with natural disease progression, should be considered when assessing treatment response in nAMD.
引用
- Tufail A, Margaron P, Guerin T, et al. Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. Br J Ophthalmol. 2019. PMID: 31562118. doi:10.1136/bjophthalmol-2018-313682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。